Literature DB >> 7116237

"Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved?".

M J Ball.   

Abstract

In the brains of patients with senile dementia of the Alzheimer type (SDAT), the quantitatively pathognomonic neuronal lesions (tangles, plaques, granulovacuolar degeneration, Hirano bodies, and nerve cell loss) are predisposed to occur especially within the limbic system. Anatomical and physiological studies indicate that fibres from the trigeminal ganglia innervate meninges and vessels within the middle and anterior cranial fossae, especially in the same subfrontal and mesial temporal regions preferentially afflicted in acute herpes encephalitis. These limbic regions are critical for normal memory processing and recall. Explantation and cocultivation techniques have recently demonstrated Herpes simplex virus in many humans trigeminal ganglia, which also reveal a life-long lymphocytic infiltration in the absence of any pathological changes in the sensory neurones. These lymphocytes may represent a histological marker of latent herpes virus, which when reactivating is well-established as the ganglionic source of recurrent herpes labialis. It is suggested that reactivation of the same dormant viral material travelling centripetally instead might be the cause of the "degenerative" lesions typical both of Alzheimer's Disease and of the normal aged human brain.

Entities:  

Mesh:

Year:  1982        PMID: 7116237     DOI: 10.1017/s0317167100044115

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  68 in total

1.  Antiviral agents in Alzheimer's disease: hope for the future?

Authors:  Matthew A Wozniak; Ruth F Itzhaki
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

2.  Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts.

Authors:  Mary Alice Allnutt; Kory Johnson; David A Bennett; Sarah M Connor; Juan C Troncoso; Olga Pletnikova; Marilyn S Albert; Susan M Resnick; Sonja W Scholz; Philip L De Jager; Steven Jacobson
Journal:  Neuron       Date:  2020-01-23       Impact factor: 17.173

Review 3.  Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy.

Authors:  M A Leissring; M C Sugarman; F M LaFerla
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

4.  Herpes simplex virus: a role in the aetiology of Alzheimer's disease?

Authors:  G W Roberts; G R Taylor; G I Carter; J A Johnson; C Bloxham; R Brown; T J Crow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-02       Impact factor: 10.154

Review 5.  On the issue of transmissibility of Alzheimer disease: a critical review.

Authors:  Christian Schmidt; André Karch; Carsten Korth; Inga Zerr
Journal:  Prion       Date:  2012-10-10       Impact factor: 3.931

Review 6.  Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  Clive Holmes; Darren Cotterell
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

7.  Could lysine supplementation prevent Alzheimer's dementia? A novel hypothesis.

Authors:  Robert N Rubey
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-27       Impact factor: 2.570

8.  APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells.

Authors:  Giovanna De Chiara; Maria Elena Marcocci; Livia Civitelli; Rafaela Argnani; Roberto Piacentini; Cristian Ripoli; Roberto Manservigi; Claudio Grassi; Enrico Garaci; Anna Teresa Palamara
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 9.  Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology.

Authors:  Melvyn J Ball; Walter J Lukiw; Eli M Kammerman; James M Hill
Journal:  Alzheimers Dement       Date:  2012-11-14       Impact factor: 21.566

Review 10.  Molecular biology of herpes simplex virus type 1 latency in the nervous system.

Authors:  I Steiner; P G Kennedy
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.